Drug Overview

Sitravatinib is an advanced, experimental cancer medication designed to attack tumors from multiple angles. It belongs to a modern group of drugs known as spectrum-selective tyrosine kinase inhibitors. Because it is designed to find and block specific proteins that help cancer grow and hide from the immune system, it is considered a Targeted Therapy and a Smart Drug.

This medication is currently being studied in clinical trials around the world. It is not available for general prescription at a local pharmacy. Patients can usually only access sitravatinib by participating in approved medical research studies, often in combination with other immune-boosting treatments.

• Generic name: Sitravatinib (also known as MGCD516)
• US Brand names: None (Investigational drug)
• Drug Class: Multi-kinase inhibitor, Targeted Therapy
• Route of Administration: Oral (taken by mouth as a capsule)
• FDA Approval Status: Investigational (Not currently approved by the FDA for standard medical use)

What Is It and How Does It Work? (Mechanism of Action)

Sitravatinib is a powerful precision medicine that blocks several different “communication lines” inside and around cancer cells. To understand how it works at the molecular level, we have to look at how tumors survive and spread.

Normally, cells use proteins called tyrosine kinases as switches to tell them when to grow. In cancer, these switches are often stuck in the “on” position. Sitravatinib works by physically blocking these switches across three main areas:

1. Stopping Growth: It blocks receptors like TAM (Tyro3, Axl, Mer), VEGFR2, and MET. By shutting down these pathways, the drug prevents the cancer cell from receiving signals to multiply.
2. Cutting Off Supplies: It interferes with the growth of new blood vessels that feed the tumor. This process is called anti-angiogenesis. Without new blood vessels, the tumor cannot get the oxygen and food it needs to grow.
3. Re-training the Immune System: This is a key Immunotherapy characteristic. The drug blocks specific receptors on immune cells that the tumor usually uses to “hide.” By blocking these TAM receptors, sitravatinib turns the environment around the tumor from “immune-suppressive” (where the immune system ignores the cancer) to “immune-active” (where the immune system attacks the cancer).

By attacking the tumor’s growth, its blood supply, and its ability to hide, sitravatinib aims to make standard immunotherapies work much better.

FDA Approved Clinical Indications

Because sitravatinib is an investigational drug, it does not have official FDA-approved uses for the general public yet. It is currently being evaluated in clinical trials for:

Oncological uses

• Investigational treatment for advanced Non-Small Cell Lung Cancer (NSCLC) that has stopped responding to other immunotherapies.
• Investigational treatment for metastatic Renal Cell Carcinoma (kidney cancer).
• Investigational treatment for advanced Melanoma.
• Investigational research for certain types of digestive system and head and neck cancers.

Non-oncological

• None at this time.

Dosage and Administration Protocols

In clinical research settings, sitravatinib is taken as an oral capsule once every day. The dose is determined by the specific clinical trial protocol.

Dose Adjustments

Because this drug is processed by the liver, doctors monitor liver function tests very closely. If liver enzymes rise too high, the dose may be lowered or paused. There is no standard dose adjustment for patients with kidney insufficiency yet, but kidney function is tracked throughout the treatment.

Clinical Efficacy and Research Results

Recent clinical research data from the 2020 to 2026 period have focused on how sitravatinib can “rescue” patients whose cancer has become resistant to other drugs.

Numerical data from the SAPPHIRE and MRTX-500 trials show that when sitravatinib is combined with nivolumab (an immunotherapy), it is active in the human body. In patients with lung cancer who had already failed previous treatments, the combination showed an objective response rate (tumor shrinkage) of approximately 18 percent to 25 percent. Furthermore, the “Disease Control Rate” (where the cancer either shrank or stayed the same size) was reported at over 60 percent in some groups. While larger Phase 3 trials have shown mixed results regarding overall survival, the drug has proven it can successfully change the immune environment of a tumor.

Safety Profile and Side Effects

Sitravatinib has a safety profile that is common for multi-kinase inhibitors. Patients are monitored closely for signs that the drug is affecting healthy organs.

Black Box Warning

There is no official FDA Black Box Warning for sitravatinib because it is an investigational drug.

Common side effects

These occur in more than 10 percent of patients:

• Diarrhea
• Feeling very tired (fatigue)
• High blood pressure (hypertension)
• Nausea and vomiting
• Skin rash or dry skin
• Hand-foot syndrome (redness and soreness on palms and soles)

Serious adverse events

• Significant increases in liver enzymes (indicating liver stress).
• Severe high blood pressure that can lead to heart problems.
• Protein in the urine (indicating kidney stress).
• Perforations (small holes) in the stomach or intestine (rare but serious).

Management strategies

To manage high blood pressure, patients often need to start or adjust blood pressure medications. For diarrhea, standard anti-diarrheal drugs are used. If side effects become severe, the medical team will lower the daily dose to 70 milligrams or 80 milligrams to help the body recover.

Research Areas

Sitravatinib is a major focus in Research Areas involving the “Tumor Microenvironment.” Scientists are studying how the drug affects the way the immune system interacts with “cancer stem cells.” Researchers believe that by blocking the TAM receptors, they can prevent these stubborn stem cells from regenerating the tumor after treatment. There is also active research into combining sitravatinib with modern immunotherapy vaccines to see if the two together can create a permanent “memory” in the immune system to keep the cancer from ever returning.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

• Blood pressure check to establish a baseline.
• Comprehensive metabolic panel to check liver and kidney function.
• Urine test to check for protein.
• Physical exam to check for existing skin issues on hands and feet.

Precautions during treatment

Patients must monitor their blood pressure at home every day. Because the drug can affect the skin, using thick, fragrance-free moisturizers on the hands and feet is recommended from the very first day.

Do’s and Don’ts list

• Do take your capsule at the same time every day, either with or without food.
• Do report any sudden or severe stomach pain or a persistent cough immediately.
• Do keep all follow-up appointments for blood work.
• Don’t ignore high blood pressure readings at home; call your oncology nurse if they are high.
• Don’t take any new herbal supplements or over-the-counter vitamins without asking your trial doctor first.
• Don’t stop taking the medication suddenly unless directed by your research team.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Sitravatinib is an investigational medication and is not approved by the FDA for the treatment of any disease. Always consult with a qualified oncologist or healthcare professional before participating in a clinical trial or starting a new medical treatment.